Secretome Therapeutics Advances Scalable Manufacturing of Regenerative Heart Therapy
Secretome Therapeutics has completed commercial-scale production of its lead therapy, STM-01, a novel treatment derived from neonatal cardiac progenitor cells (nCPC) for heart failure and dilated cardiomyopathy. The milestone, achieved in collaboration with RoosterBio Inc., marks the successful scale-up of STM-01 production from a 2D flask process to a 50L cGMP-compatible bioreactor system, significantly improving productivity and scalability for future clinical manufacturing. The process incorporates RoosterBio’s advanced cell expansion and feed media systems: enabling efficient, cost-effective production of Secretome’s pioneering secretome-based therapy. STM-01 is currently in Phase I clinical trials for the treatment of heart failure with preserved ejection fraction (HFpEF) and dilated cardiomyopathy (DCM).
Secretome Therapeutics Advances Scalable Manufacturing of Regenerative Heart Therapy